Zarnovicanová M, Pelikánová S
Hematologické oddelenie, Regionálne centrum hemostázy a trombózy, NsP F. D. Roosevelta, Banská Bystrica, Slovenská republika.
Vnitr Lek. 2003 Apr;49(4):319-21.
Isolated reduced coagulation activity of FVIII may be a manifestation of haemophilia A, carriership of haemophilia A, haemophilia A in a woman, acquired haemophilia A and type 2N of von Willebrand's disease. The authors were concerned with the cause of isolated reduction of the coagulation activity of factor VIII (19 IU/dl) in a 40-year-old woman with a history of excessive haemorrhage of the type of mild haemophilia A with a negative family history. The personal history, family history and laboratory examination suggested type (variant) 2N of von Willebrand's disease. For indirect evidence the authors used a therapeutic study where they investigated the effect of administration of a concentrate of coagulation factors VIII/von Willebrand's factor (1/2), 28 IU factor VIII/kg body weight, on the coagulation activity of factor VIII. They recorded a half-life prolonged to 53 hours as compared with controls where the half-life was less than 12 hours. The therapeutic study confirmed sufficient coagulation activity of factor VIII, the utilization of which improved as a result of administration of von Willebrand's factor. This investigation confirmed indirectly as the cause of reduced coagulation activity of factor VIII in the examined patient the assumed type (variant) 2N of von Willebrand's disease.
孤立性FVIII凝血活性降低可能是甲型血友病、甲型血友病携带者、女性甲型血友病、获得性甲型血友病以及2N型血管性血友病的表现。作者关注的是一名40岁女性,有轻度甲型血友病类型的过度出血史且家族史阴性,其VIII因子凝血活性孤立性降低(19IU/dl)的原因。个人史、家族史及实验室检查提示为血管性血友病2N型(变异型)。作为间接证据,作者进行了一项治疗性研究,研究给予凝血因子VIII/血管性血友病因子浓缩物(1/2),即28IU VIII因子/千克体重,对VIII因子凝血活性的影响。他们记录到与半衰期小于12小时的对照组相比,半衰期延长至53小时。该治疗性研究证实VIII因子有足够的凝血活性,由于给予血管性血友病因子,其利用率得到改善。这项调查间接证实,所检查患者VIII因子凝血活性降低的原因是假定的血管性血友病2N型(变异型)。